AMS
American Shared Hospital Services
AMS trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over AMS overall, supported by lower modeled downside and stronger fundamentals.
AMS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
AMS's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMS PE Valuation
AMS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
AMS Forward outlook
There aren't enough analyst estimates for AMS to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
AMS Earnings Per Share
AMS and LLY do not have enough comparable growth data to identify a winner.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
AMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $8.4M | +19% |
| Q1 2026 | $7.1M | +16% |
| Q4 2025 | $7.7M | -15% |
| Q3 2025 | $7.2M | +2.5% |
| Q2 2025 | $7.1M | +0.2% |
| Q1 2025 | $6.1M | +17% |
| Q4 2024 | $9.1M | +59% |
| Q3 2024 | $7M | +36% |
AMS's revenue has held roughly level: $8M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -11% | -3.1 points |
| Q1 2026 | -13% | +8.2 points |
| Q4 2025 | -18% | +2.1 points |
| Q3 2025 | -4.8% | +7.9 points |
| Q2 2025 | -7.7% | -7.7 points |
| Q1 2025 | -21% | -20 points |
| Q4 2024 | -20% | -27 points |
| Q3 2024 | -13% | -14 points |
AMS's operating margin was −11% last quarter, down 3.1 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over AMS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over AMS on profitability, with a higher operating margin.
AMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +$4.5M |
| Q1 2026 | $2.1M | +$3.6M |
| Q4 2025 | $1.3M | +$5.7M |
| Q3 2025 | -$2M | -$1.6M |
| Q2 2025 | -$2.3M | -3347% |
| Q1 2025 | -$1.5M | +$1.5M |
| Q4 2024 | -$4.4M | -$1.2M |
| Q3 2024 | -$407K | -$356K |
AMS's free cash flow has turned positive after two years mostly in the red: $4M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over AMS on cash flow, with more consistent year-over-year improvement.
AMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +147K shares |
| 1 year | +4.4% | +290K shares |
| 3 years | +8.5% | +536K shares |
| 5 years | +18% | +1.1M shares |
| Available history | +16% | +964K shares |
AMS has 7M diluted shares, up 4.4% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over AMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
AMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 5.3x | High |
| Q1 2026 | 5.1x | High |
| Q4 2025 | 6.5x | High |
| Q3 2025 | 6.3x | High |
| Q2 2025 | 4.7x | High |
| Q1 2025 | 3.8x | Elevated |
| Q4 2024 | 2.7x | Moderate |
| Q3 2024 | 0.1x | Very low |
AMS's net debt is about 5.3 years of its operating earnings (EBITDA), up from 4.7 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over AMS on leverage, with a lower net debt burden relative to earnings.
AMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.1 | Neutral |
| Stochastic | 11.8 | Oversold |
AMS's weekly RSI is 30 (neutral) and its Stochastic is 12 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
AMS PE vs Healthcare Sector
| Metric | AMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
AMS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
AMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.28 | 15% below |
| 20 week MA | $1.39 | 22% below |
| 50 week MA | $1.66 | 34% below |
| 100 week MA | $2.15 | 49% below |
| 200 week MA | $2.51 | 57% below |
AMS is in a downtrend: it's below all five of its weekly moving averages, and 57% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over AMS on trend strength, trading above more of its moving averages.
AMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2.56 | $2.10 | -18% |
| 2021 | $2.10 | $2.42 | +15% |
| 2022 | $2.42 | $2.81 | +16% |
| 2023 | $2.81 | $2.38 | -15% |
| 2024 | $2.38 | $3.19 | +34% |
| 2025 | $3.19 | $2.14 | -33% |
| 2026 YTD | $2.14 | $1.09 | -49% |
AMS has finished lower in three of the last six years. It's down 49% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over AMS on returns for 2026, with the stronger performance.